

Avagenesis and Avapecia Announce the Appointment of Dr. Peter Lennox as Medical Advisor

August 22, 2016 – Calgary, Alberta and Richmond, British Columbia: Avagenesis Corp. and Avapecia Life Sciences Corp. (“Company” or the “Companies”) are pleased to announce the appointment of Dr. Peter Lennox, MD FRCSC, as medical advisor.

Dr. Peter Lennox is the Head of the UBC Division of Plastic Surgery, former Head of the Plastic Surgery Residency training program, Director of the Breast Reconstruction program, Clinical Associate professor in the UBC Faculty of Medicine and is an RCPSC certified plastic surgeon in Vancouver.

He is a Fellow of the Royal College of Physicians and Surgeons of Canada, President of the Canadian Society of Plastic Surgeons, Secretary/Treasurer of the Canadian Society of Aesthetic Plastic Surgeons and past President of the Northwest Society of Plastic Surgeons.

Dr. Lennox has been the author of numerous articles in prestigious scholarly journals such as the *Annals of Plastic Surgery* and *Plastic and Reconstructive Surgery*, a frequent speaker and lead presenter at national and international conferences.

About Avagenesis Corp.

Avagenesis is a biotechnology company engaged in the commercialization of licensed cell isolation medical technologies for use in regenerative medical aesthetics, wound management and non-healing wounds, cardiovascular and heart diseases, peripheral arterial disease, critical limb ischemia or diabetic leg, hepatic disease and kidney disease.

About Avapecia Life Sciences Corp.

Avapecia is a biotechnology company engaged in the research, development and commercialization of regenerative stem cell technologies and therapy solutions for use in urogynaecology, urology, hair loss (prevention, maintenance, and regeneration), gastrointestinal diseases, respiratory medicine, neurodegenerative diseases, ophthalmology, spinal cord injuries and certain autoimmune diseases. Avapecia’s bioprocessing platform provides third party validated and standardized isolation of safe, high quality, viable, and potent stem cells from a patient’s own fat, or adipose tissue, for use in current and future cell therapy applications.

Neither the TSX Venture Exchange or Canadian Securities Exchange nor their respective regulation services providers (as that term is defined in their respective policies) accepts responsibility for the adequacy or accuracy of this press release.

Cautionary Statements

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", “likely”, "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on current belief or assumptions as to the outcome and timing of such future events. Actual future results and developments may differ materially from those contemplated by these statements depending on, among other things, the risk that the Company may not successfully transition to a clinical stage company and successfully execute its development and commercialization activities. Various

assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to the Company. Readers are cautioned that the above list of risk factors is not exhaustive. The forward-looking information contained in this press release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

Further Information

For further information, please contact:
Avagenesis Corp. or Avapecia Life Sciences Corp.
Alan Tam, CPA, CA
Chief Financial Officer
Telephone: (604) 377-7575